Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atricure Inc (NQ: ATRC )

23.45 +0.35 (+1.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,057,560
Open 23.19
Bid (Size) 23.07 (1)
Ask (Size) 23.86 (1)
Prev. Close 23.10
Today's Range 23.14 - 24.01
52wk Range 22.41 - 59.61
Shares Outstanding 45,882,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Key Takeaways From AtriCure Analyst Ratings
Via Benzinga
AtriCure to Announce First Quarter 2024 Financial Results
From AtriCure, Inc.
Via Business Wire

Performance

YTD
-33.61%
-33.61%
1 Month
-26.58%
-26.58%
3 Month
-29.81%
-29.81%
6 Month
-34.63%
-34.63%
1 Year
-43.72%
-43.72%

More News

Read More
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For AtriCure
Via Benzinga
Recap: AtriCure Q4 Earnings
Via Benzinga
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
Earnings Scheduled For February 15, 2024
Via Benzinga
AtriCure's Earnings: A Preview
Via Benzinga
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference
From AtriCure, Inc.
Via Business Wire
Key Takeaways From AtriCure Analyst Ratings
Via Benzinga
Where AtriCure Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024
From AtriCure, Inc.
Via Business Wire
AtriCure Appoints Shlomi Nachman to the Board of Directors
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From AtriCure
Via Business Wire
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Releases 2023 ESG Report
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Third Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the Stifel 2023 Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Third Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Second Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate at Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Second Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.